In Cancer TreatmentLearn More
Salarius is a cancer-focused biotechnology company developing treatments for patients who need them the most.
Our technology targets the epigenetic causes of cancer which is the study of the regulatory system that controls how genes are turned “on” or “off.” In certain cancers, the proteins that regulate gene expression become dysregulated and incorrectly turn genes “on” or “off,” which in some cases leads to cancer progression. Drugs that are able to safely modify the activity of these epigenetic regulators may correct the gene changes that are driving disease. Our technology may also apply to hormonal cancers such as prostate, breast, ovarian cancer and perhaps other conditions like leukemia.
Salarius is the recipient of a 3-year $18.7 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award, is housed in the Jlabs@TMC facility in Houston, Texas and receives support from organizations like the National Pediatric Cancer Foundation.
News & Events
Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma
Phase 1/2 Clinical Study Now Underway; Salarius Targeting Key Safety and Efficacy Data Milestones in 2020